Project Grant F32CA288043
Award Date
7/31/24
Completion Date
3/31/25
Dollars Obligated
$220K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award of $566,998.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting acute myeloid leukemia (AML) using a CD123-directed NK-cell engager and NK cell immune therapy, as well as harnessing the apoptotic machinery through BCL-2 inhibition. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period from September 30, 2024 to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $542,663 to The University of Texas MD Anderson Cancer Center to conduct preclinical research on using BRG1/BRM antagonists to treat acute myeloid leukemia (AML) with MLL rearrangement or mutant NPM1. The research aims to determine the efficacy of BRG1/BRM inhibitor and degrader compounds, evaluate combination regimens with these agents, and overcome resistance to menin inhibitors...
The National Cancer Institute (NCI) awarded a $237,023 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 3-year award (3/1/2025 - 2/29/2028) will fund the development and optimization of a scalable, high-throughput single-cell method (SHARE-ME-SEQ) to simultaneously profile gene expression, chromatin accessibility, and DNA methylation in acute myeloid leukemia (AML) samples. Researchers will apply this technology to analyze bone marrow...
This Project Grant award of $458,698.00 was provided by the National Cancer Institute (NCI) under the federal Cancer Biology Research program (CFDA 93.396). The award, effective March 10, 2025 through February 28, 2030, supports research to identify novel genes and mechanisms underlying therapy resistance and relapse in acute myeloid leukemia (AML). The research aims to functionally validate candidate genes from prior single-cell RNA sequencing and CRISPR screens in order to better understand...
The National Cancer Institute (NCI), under the Cancer Treatment Research (CFDA 93.395) federal grant program, awarded a $734,435 Project Grant to the Beckman Research Institute of the City of Hope on March 10, 2025. The grant supports research to overcome resistance to BH3 mimetic drugs, a targeted therapy for acute myeloid leukemia (AML), by inhibiting the ADSS2 enzyme involved in AMP biosynthesis. The research aims to: 1) Correlate ADSS2 levels with BH3 mimetic responsiveness in primary AML...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $165,247 to President and Fellows of Harvard College (Harvard Medical School) to conduct research on the MECOM gene and its regulation in high-risk acute myeloid leukemia (AML). The key objectives are to: (1) identify the direct genetic targets of the MECOM transcription factor in high-risk AML, and (2) elucidate the epigenetic mechanisms by which MECOM represses differentiation programs...
The National Cancer Institute (NCI) awarded a $487,973 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University (Stanford University) to investigate key questions related to pre-leukemic hematopoietic stem cell (PHSC) clonal evolution, kinetics, and cell non-autonomous effects in acute myeloid leukemia (AML) pathogenesis. The 5-year grant, which commenced on January 1, 2025, aims to provide novel insights into the genetic events and cellular kinetics that...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
This $1,600,000.00 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at Baylor College of Medicine focused on developing new synthetic lethal combination therapies targeting TopBP1 and the arachidonic acid pathway for breast cancer treatment. The three-year award, with an end date of February 28, 2027, will fund basic, translational, and clinical research aimed at advancing scientific understanding and...
The National Cancer Institute (NCI) awarded a 5-year, $487,542 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Beckman Research Institute of the City of Hope to conduct research on targeting mitochondrial RNA methylation in high-risk acute myeloid leukemia (AML). The key objectives of the project are to: Determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis using mouse models. Elucidate the molecular mechanisms by which METTL17...